Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
06. Juni 2023 10:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
05. Juni 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
03. Juni 2023 14:15 ET
|
Replimune Group Inc
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no...
Replimune to Present at the Jefferies Global Healthcare Conference
01. Juni 2023 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
25. Mai 2023 17:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
18. Mai 2023 08:00 ET
|
Replimune Group Inc
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
09. Mai 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at Two Upcoming Investor Conferences
08. März 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
09. Februar 2023 08:00 ET
|
Replimune Group Inc
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline...
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
07. Februar 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...